A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...

A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Novo Nordisk is a bargain stock with tremendous growth potential. Vertex Pharmaceuticals has seven clear paths to growth ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...